Company Directory > Biotech > Aristo Pharmaceuticals Private Limited
Aristo Pharmaceuticals is a prominent Indian pharmaceutical company established in 1971. It focuses on developing, manufacturing, and marketing a wide range of branded pharmaceutical formulations across various therapeutic segments, including antibiotics, anti-hypertensives, and anti-diabetics. The company has a significant presence in both domestic and international markets, operating multiple state-of-the-art, cGMP-compliant manufacturing facilities in India. Aristo is known for its strong focus on R&D, brand building, and ethical marketing practices. It is consistently ranked among the top Indian-owned pharmaceutical organizations by turnover and prescription volume, maintaining a robust growth trajectory in the Indian pharmaceutical market.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Branded Formulations
SIZE & FINANCIALS
Employees:10000+
Revenue:₹5,360Cr (FY2025)
Founded:1971
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Leader
Competitors:Cipla, Mankind Pharma, Sun Pharmaceutical Industries, Torrent Pharmaceuticals, Indoco Remedies
LEADERSHIP
Key Executives:
Mahendra Prasad - CEO
Umesh Sharma - Director
Virendra Sharma - Director
Board Members:Umesh Sharma, Virendra Sharma, Randhir Kumar Bachan
LINKS
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Aristo Pharmaceuticals Private Limited and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Aristo Pharmaceuticals Private Limited. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.